Core Scientific Revenue Falls 44 Percent

Core Scientific reported a weak Q2 FY2025, with GAAP revenue of $78.6 million missing estimates and declining 44.2% year-over-year, and gross profit collapsing 87.1% to $5.0 million, primarily due to ongoing pressures in its legacy bitcoin mining segment. Despite colocation revenue nearly doubling to $10.6 million, driven by AI computing growth and the CoreWeave contract, the company faces significant client concentration risk. This performance highlights the challenges of its strategic pivot from volatile bitcoin mining to digital infrastructure, a transition now set to accelerate following the recently announced all-stock acquisition proposal by its key customer, CoreWeave.

Analysis

Core Scientific's Q2 FY2025 results reveal a company under significant operational and financial pressure during a critical strategic pivot, a situation now dominated by a pending acquisition. GAAP revenue of $78.6 million missed consensus by 6.2% and fell 44.3% year-over-year, driven by a sharp deterioration in the legacy bitcoin mining business where gross margins collapsed to 5%. This erosion led to a consolidated gross profit of just $5.0 million, an 87.1% decrease from the prior year. While the strategic shift toward AI-focused colocation shows promise, with revenue nearly doubling year-over-year to $10.6 million, this growth is entirely dependent on a single client, CoreWeave. This high-risk customer concentration is underscored by the fact that CoreWeave funded the majority ($90.3 million) of the quarter's capital expenditures. The company's financial health is further strained by a significant cash reduction of over $250 million in the first six months of 2025. Ultimately, the quarter's poor performance is largely overshadowed by the announced all-stock merger with CoreWeave, which, if approved, will exchange each Core Scientific share for 0.1235 shares of CoreWeave, fundamentally reframing the investment case from an operational turnaround to an M&A arbitrage scenario.

Key Decisions for Investors

• The investment thesis for Core Scientific has fundamentally shifted from a standalone operational turnaround to the successful completion of the all-stock acquisition by CoreWeave; valuation should now be primarily assessed based on the merger's probability and the implied value of the 0.1235 share exchange ratio.
• Given the severe 87.1% decline in gross profit and collapsing margins in the core mining segment, investors must consider the significant standalone risk if the merger fails to close, as the company is burning cash and is wholly dependent on CoreWeave for its strategic growth.
• Key catalysts to monitor are progress on regulatory and shareholder approvals for the merger, while the primary operational metric to watch is the signing of any new, large-scale colocation clients to mitigate the extreme customer concentration risk.